VEGF antagonist formulations

Details for Australian Patent Application No. 2006229930 (hide)

Owner Regeneron Pharmaceuticals, Inc.

Inventors Dix, Daniel; Kautz, Susan; Frye, Kelly

Agent Phillips Ormonde Fitzpatrick

Pub. Number AU-B-2006229930

PCT Pub. Number WO2006/104852

Priority 60/665,125 25.03.05 US

Filing date 22 March 2006

Wipo publication date 5 October 2006

Acceptance publication date 5 August 2010

International Classifications

A61K 38/17 (2006.01) Medicinal preparations containing peptides - from animals

A61K 47/00 (2006.01) Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives

Event Publications

6 September 2007 PCT application entered the National Phase

  PCT publication WO2006/104852 Priority application(s): WO2006/104852

5 August 2010 Application Accepted

  Published as AU-B-2006229930

2 December 2010 Standard Patent Sealed

6 September 2012 Extension of Term of Standard Patents

  Regeneron Pharmaceuticals, Inc. The earliest first regulatory approval date provided by the patentee 07 Mar 2012 For the goods EYLEA aflibercept

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2006229932-Automated offer management using audience segment information

2006229917-Multiwell sample plate with integrated impedance electrodes and connection scheme